肝动脉化疗栓塞联合卡培他滨治疗原发性肝癌的临床观察

Clinical Study of TACE Combined with Capecitabine Treat Primary Hepatic Carcinoma Patients

目的观察TACE联合卡培他滨对原发性肝癌患者生存的影响。方法原发性肝癌患者57例,分为TACE联合卡培他滨组和TACE组:TACE联合组28例,采用肝动脉化疗栓塞联合卡培他滨治疗;TACE组29例,单纯采用肝动脉化疗栓塞治疗。观察两组患者的疗效及患者的生存时间。结果 TACE联合组RR为32.1%,TACE组RR为10.3%,两组RR的差异有统计学意义(P<0.05)。TACE组的中位生存期为10.0个月,1年生存率37.9%,TACE联合组的中位生存期为16.3个月,1年生存率60.7%,均优于TACE组,差异有统计学意义(P<0.05)。结论 TACE联合卡培他滨可显著提高肝癌患者的疗效,延长生存时间。

Objective To observe the effects of TACE combined with capecitabine on the survival of primary hepatic carcinoma patients. Methods The 57 primary hepatic carcinoma patients were collected. The patients were divided into observation and control groups. The 28 patients in the observation group received TACE combined with capecitabine. The 29 patients in the control group received TACE only. The curative effects, survival time, 1 year survival rates were observed. Results The total RR of the observation group was 32.1%, which was signiifcantly higher than that of the control group （10.3%）. Moreover, the 1 year survival rate of the observation group was 60.7%, which was signiifcantly higher than that of the control group （37.9%）. The signiifcant differences in RR and OS were observed between the two groups （P〈0.05）. Conclusion TACE combined with capecitabine could improve the curative effect, prolong the survival time of primary hepatic carcinoma patients.